Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
Wijzigingsgeschiedenis
First seen 28 Sept 2026, last checked 22 Nov 2026. 20 recorded versions.
- 22 Oct 2026 · c891af6680af
- 22 Oct 2026 · 751b62f6caf9
- 21 Oct 2026 · eb3c029cdc28
- 20 Oct 2026 · 0b72e604510c
- 19 Oct 2026 · 77b5db67bc13
- 18 Oct 2026 · eb9f28cd6967
- 17 Oct 2026 · 7eaa13bc05bb
- 16 Oct 2026 · 1cb466a742a2
- 15 Oct 2026 · 807de96c6d72
- 14 Oct 2026 · 893a02f83559
- 13 Oct 2026 · f6b728ff2c86
- 12 Oct 2026 · 457945800fd9
- 11 Oct 2026 · a4b342763bbb
- 10 Oct 2026 · f573b0a89332
- 09 Oct 2026 · 27a8b07c4275
- 08 Oct 2026 · dcc733ffb6bd
- 07 Oct 2026 · 27a8b07c4275
- 06 Oct 2026 · cec72b59a79c
- 05 Oct 2026 · 4aba15ac8e03
- 04 Oct 2026 · 310610cd2b68